A5038614516- Cancer Immunotherapy and Biomarkers
- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- Health Systems, Economic Evaluations, Quality of Life
- Economic and Financial Impacts of Cancer
- Pharmaceutical Economics and Policy
- Renal cell carcinoma treatment
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Renal and related cancers
- Colorectal Cancer Treatments and Studies
- Food Security and Health in Diverse Populations
- Indigenous Studies and Ecology
- Bone health and treatments
- Indigenous Health, Education, and Rights
- CAR-T cell therapy research
- Lung Cancer Research Studies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Neurological Complications and Syndromes
- Neuroblastoma Research and Treatments
- Radiology practices and education
- Cancer survivorship and care
- Inflammatory mediators and NSAID effects
- Innovations in Medical Education
- Healthcare Policy and Management
William Osler Health System
2014-2024
University of Alberta
2009-2024
Alberta Health
2022-2024
Alberta Health Services
2022-2024
Government of Northwest Territories
2022-2024
University of British Columbia
2022-2024
Roche (Canada)
2023-2024
Roche (Switzerland)
2022-2024
Western University
2014-2023
The University of Texas MD Anderson Cancer Center
2012-2014
Cytotoxic agents have immunomodulatory effects, providing a rationale for combining atezolizumab (anti-programmed death-ligand 1 [anti-PD-L1]) with chemotherapy. The randomized phase III IMpower131 study (NCT02367794) evaluated platinum-based chemotherapy in stage IV squamous NSCLC.A total of 1021 patients were 1:1:1 to receive atezolizumab+carboplatin+paclitaxel (A+CP) (n = 338), atezolizumab+carboplatin+nab-paclitaxel (A+CnP) 343), or carboplatin+nab-paclitaxel (CnP) 340) four six 21-day...
LBA9000 Background: Atezolizumab (atezo; anti–PD-L1) demonstrated OS benefit vs docetaxel in 2L+ NSCLC regardless of PD-L1 status or tumor histology. Because cytotoxic agents can exhibit positive immunomodulatory effects, combining atezo with chemotherapy may further improve outcomes. IMpower131 (NCT02367794) was designed to evaluate + carboplatin (carbo) paclitaxel (pac) nab-paclitaxel (nab-pac) 1L stage IV squamous NSCLC. Methods: Patients (pts) were randomized 1:1:1 Arm A (atezo 1200 mg...
Patients with metastatic castration-resistant prostate cancer (mCRPC) frequently receive docetaxel after they develop resistance to abiraterone or enzalutamide and need more efficacious treatments. To evaluate the efficacy safety of pembrolizumab plus prednisone in patients mCRPC. The trial included mCRPC phase 1b/2 KEYNOTE-365 cohort B study who were chemotherapy naïve experienced failure intolerant ≥4 wk for progressive disease within 6 mo screening. Pembrolizumab 200 mg intravenously (IV)...
Background. Staging and treatment of adult neuroblastoma has yet to be formalized. We sought determine the utility pediatric classification system in adults efficacy different modalities. Methods. Medical records 118 (patients >17 years old) 112 patients (ages 2-17), who were treated for at M.D. Anderson Cancer Center from January 1994 September 2012, reviewed. International risk group (INRG) variables abstracted. The primary outcome interest was actuarial progression-free survival. Results....
Aim: To assess the cost-effectiveness in Canada of atezolizumab compared with docetaxel or nivolumab for treatment advanced NSCLC after first-line platinum-doublet chemotherapy.Materials and methods: A three-state partitioned-survival model was developed. Clinical inputs were obtained from phase III OAK trial comparing patients who progressed chemotherapy. Overall survival (OS) progression-free (PFS) extrapolated beyond period using parametric models. cure assuming a 1% fraction fitted to OS...
Background and objectiveAbiraterone acetate (abiraterone) plus prednisone is approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Our aim was to evaluate efficacy safety pembrolizumab abiraterone in mCRPC.MethodsIn cohort D phase 1b/2 KEYNOTE-365 study (NCT02861573), patients were chemotherapy-naïve, had disease progression ≤6 mo before screening, either not received prior next-generation hormonal agents mCRPC or enzalutamide became intolerant enzalutamide....
171 Background: Pembro has antitumor activity as monotherapy in pretreated advanced mCRPC (KEYNOTE-028; KEYNOTE-199). A study suggested that pembro + enza after progression on may have clinical activity. KEYNOTE-365 (NCT02861573) is a phase 1b/2 umbrella testing combinations mCRPC; we report early results from cohort C combining mCRPC. Methods: Patients who failed or became intolerant to ≥4 weeks of abi the pre-chemotherapy state were included. Pts also had progressed within 6 months prior...
102 Background: KEYNOTE-365 (NCT02861573) is a phase 1b/2 study evaluating pembro in combination with other agents mCRPC. An earlier report of cohort C showed activity and acceptable safety + enza. Updated results from are reported. Methods: Pts who failed or became intolerant to ≥4 wks abi prechemotherapy mCRPC state whose disease progressed within 6 mo screening per PSA progression radiologic bone soft tissue enrolled. received 200 mg IV Q3W enza 160 mg/day PO. Primary end points: safety,...
103 Background: KEYNOTE-365 (NCT02861573) is a phase 1b/2 study to evaluate pembro in combination with other agents mCRPC. Here we report updated results from cohort B (pembro + docetaxel and prednisone). Methods: Cohort enrolled pts who failed or were intolerant ≥4 wk of abi enza the prechemotherapy mCRPC state whose disease progressed within 6 mo screening as determined by PSA progression radiologic bone/soft tissue progression. Pts received 200 mg IV 75 mg/m 2 Q3W prednisone 5 orally...
Advanced RCC has seen many treatment advances in the last several years, with introduction of novel therapies. Recent evidence from KEYNOTE 426 and CheckMate 214 studies mandated a rearrangement algorithms for advanced clear-cell RCC. We now await both clinical experience prospective trials to help inform optimal sequence therapy these newer therapies, VEGF-targeted therapies other evidence-based options. Ongoing participation research further our knowledge this field continues be an...
10 Background: For men with mCRPC, systemic therapies such as docetaxel and cabazitaxel improve survival, but more effective treatments are needed. KEYNOTE-365 (NCT02861573) is a phase 1b/2 study to examine the safety efficacy of pembro in combination 4 different medications (cohorts A, B, C, D) mCRPC. Previous data from cohort B median 20 months follow-up showed that + prednisone was well tolerated had antitumor activity patients (pts) mCRPC previously treated abi or enza. New after an...
Abstract Purpose While adjuvant bisphosphonate use in early breast cancer (EBC) is associated with improvements cancer-specific outcomes, questions remain around optimal type, dose and scheduling. We evaluated a single zoledronate infusion prospective randomised trial. Methods Postmenopausal patients EBC were to receive of (4 mg IV) or 6-monthly treatment for 3 years. Outcomes measured were; Quality Life (QoL; EQ-5D-5L), bisphosphonate-related toxicities, including acute phase reactions...
Adjuvant zoledronate is widely used in patients with early stage breast cancer (EBC), but its optimal duration and dosing interval still unknown. While a single-dose of can improve bone density for many years, proper evaluation effects on cancer-related outcomes would require large trial. In this pilot study we evaluated the feasibility performing such trial.Eligible EBC were randomised to receive either one dose or 7 doses (6-monthly 3 years). Feasibility was assessed by combination primary...
N/A
Introduction: Treatment using abiraterone acetate plus prednisone, enzalutamide, cabazitaxel, and radium-223 (Ra-223) improves overall survival (OS) quality of life for patients with metastatic castrate-resistant prostate cancer (mCRPC). Despite their proven benefits, access to these therapies is not equal across Canada.Methods: We describe provincial differences in approved mCRPC therapies. Data sources include the pan-Canadian Oncology Drug Review database, care resources, correspondence...
5550 Background: Pembro + docetaxel and prednisone (cohort B) has shown antitumor activity in pts with mCRPC the phase I/II KEYNOTE-365 study (NCT02861573). Updated efficacy safety new biomarker data from cohort B are reported. Methods: Pts who received at least 4 wk of abi or enza prechemotherapy setting whose disease progressed within 6 mo screening were eligible. pembro 200 mg IV 75 mg/m 2 Q3W 5 orally twice daily. Primary end points PSA response rate (PSA decrease ≥50%; confirmed by a...
5010 Background: Pembro has activity as monotherapy in pts with pretreated advanced mCRPC. A phase 2 study suggested that pembro + enza after progression on may have clinical activity. Data from cohort C (pembro enza) of KEYNOTE-365 (NCT02861573), a 1b/2 umbrella to test combinations mCRPC, are presented. Methods: Pts who were unsuccessful or became intolerant ≥4 weeks abi the prechemotherapy mCRPC state, either PSA radiologic within 6 mo before screening included. received 200 mg IV Q3W 160...
You have accessJournal of UrologyProstate Cancer: Advanced (including Drug Therapy) II (PD16)1 Apr 2020PD16-12 PEMBROLIZUMAB PLUS ENZALUTAMIDE IN ABIRATERONE-PRETREATED PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: UPDATED RESULTS FROM KEYNOTE-365 COHORT C Evan Y. Yu*, Peter Fong, Josep M. Piulats, Leonard Appleman, Henry Conter, Susan Feyerabend, Neal Shore, Gwenaelle Gravis, Brigitte Laguerre, Howard Gurney, Margitta Retz, Emanuela Romano, Loic Mourey, Johann S. de Bono,...